- Home
- TRMD vs ARQT Comparison
TRMD vs ARQT Comparison
Compare TRMD & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- ARQT
- Stock Information
- Founded
- TRMD 1889
- ARQT 2016
- Country
- TRMD United Kingdom
- ARQT United States
- Employees
- TRMD N/A
- ARQT N/A
- Industry
- TRMD Marine Transportation
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- ARQT Health Care
- Exchange
- TRMD Nasdaq
- ARQT Nasdaq
- Market Cap
- TRMD 2.1B
- ARQT 2.1B
- IPO Year
- TRMD N/A
- ARQT 2020
- Fundamental
- Price
- TRMD $20.36
- ARQT $20.74
- Analyst Decision
- TRMD Buy
- ARQT Strong Buy
- Analyst Count
- TRMD 1
- ARQT 7
- Target Price
- TRMD $23.00
- ARQT $19.00
- AVG Volume (30 Days)
- TRMD 649.5K
- ARQT 1.9M
- Earning Date
- TRMD 11-06-2025
- ARQT 10-28-2025
- Dividend Yield
- TRMD 12.76%
- ARQT N/A
- EPS Growth
- TRMD N/A
- ARQT N/A
- EPS
- TRMD 3.31
- ARQT N/A
- Revenue
- TRMD $1,321,800,000.00
- ARQT $263,464,999.00
- Revenue This Year
- TRMD N/A
- ARQT $72.46
- Revenue Next Year
- TRMD N/A
- ARQT $31.69
- P/E Ratio
- TRMD $6.16
- ARQT N/A
- Revenue Growth
- TRMD N/A
- ARQT 99.50
- 52 Week Low
- TRMD $13.60
- ARQT $8.03
- 52 Week High
- TRMD $33.15
- ARQT $21.30
- Technical
- Relative Strength Index (RSI)
- TRMD 40.33
- ARQT 68.31
- Support Level
- TRMD $20.41
- ARQT $16.68
- Resistance Level
- TRMD $21.98
- ARQT $21.30
- Average True Range (ATR)
- TRMD 0.46
- ARQT 1.00
- MACD
- TRMD -0.22
- ARQT 0.25
- Stochastic Oscillator
- TRMD 2.90
- ARQT 89.84
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.